Jyothy Labs (532926) Q4 12/13 earnings summary

Executive summary

• FY13 results reflect a full year of Jyothy Consumer Products Ltd. after its merger, effective April 1, 2012; prior-year standalone comparisons are not like-for-like.

• Standalone net sales rose 53.5% to ₹1,01,738 lakh; reported PAT fell to ₹4,404 lakh, largely due to ₹4,471 lakh of goodwill and brand amortization.

• Integration priorities included business-model redesign, distribution consolidation, manufacturing efficiencies, stronger management systems and brand investment.

Financial highlights

• Standalone total revenue increased 48.4% to ₹1,06,859 lakh; net sales grew 53.5% to ₹1,01,738 lakh.

• Standalone EBITDA was ₹12,374 lakh, with a 12.2% margin versus 12.5% in FY12; statutory P&L EBITDA was ₹12,543 lakh.

• Standalone PAT was ₹4,404 lakh versus ₹8,352 lakh; adjusted for ₹4,471 lakh amortization of acquired goodwill, copyrights and trademarks, PAT was ₹8,874 lakh.

• Consolidated revenue was ₹1,10,721 lakh, EBITDA ₹13,091 lakh and PAT after minority interest ₹1,965 lakh; consolidated EPS was ₹1.18.

Outlook and guidance

• FY14 priorities: strengthen brands with new creative campaigns and marketing spend, leverage redesigned distribution, sustain production efficiency and target growth above the industry mean.

• Operational focus included improving working-capital management, capacity utilization, manufacturing strategy, demand forecasting and brand growth.

• A Mumbai R&D laboratory was established following integration; planned work includes product testing, benchmarking, cost reduction and innovation partnerships.

• Bangladesh commercial production was expected to begin in Q2 FY14.